Evaluating sleeve lobectomy techniques for lung cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study aims to assess the long-term survival and perioperative outcomes of sleeve lobectomy performed using robotic-assisted thoracic surgery (RATS) compared to video-assisted thoracic surgery (VATS) for patients with centrally located non-small cell lung cancer (NSCLC). The study will analyze data from participants who underwent these minimally invasive surgical techniques between January 2015 and September 2024. By focusing on a high-volume cohort, the researchers seek to determine if RATS offers similar or improved outcomes compared to VATS in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years;
* Clinically suspected lung cancer with a high likelihood of undergoing sleeve lobectomy;
* Postoperative histopathological diagnosis confirms non-small cell lung cancer (NSCLC);
* No history of malignancy within the past 5 years;
* Signed informed consent agreeing to participate in this study.

Exclusion Criteria:

* Unable to undergo surgical resection due to surgical contraindications;
* Postoperative pathology does not confirm non-small cell lung cancer (NSCLC), including but not limited to benign lesions, small cell lung cancer, metastatic tumors, or an insufficient or indeterminate histopathology report;
* History of malignancy within the past 5 years;
* Unable to obtain follow-up data;
* Refusal to sign the informed consent or withdrawal of consent.

Where it's running

• The Second Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, China Recruiting
• Sir Run Run Shaw Hospital, Medical College, Zhejiang University
  Hangzhou, China Recruiting
• Shanghai Chest Hospital, Shanghai Jiao Tong University
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Haifeng Shen, M.D. — Second Affiliated Hospital, Zhejiang University, School of Medicine
• Study coordinator: Haifeng Shen, M.D.
• Email: shenhaifeng@zju.edu.cn
• Phone: +86 13634197989

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations

  This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07405190

• Personalized exercise plan for cancer survivors

  This study tests a personalized, physician-guided exercise program for adults who have completed cancer treatment, to see if a safe, structured plan can be implemented in routine care.

  Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan · NCT07751783

• Abdominal pressure device to control breathing during stereotactic radiotherapy for peripheral non-small cell lung cancer

  This project tries an abdominal pressure device to reduce breathing-related tumor movement during stereotactic radiotherapy for people with solitary peripheral non-small cell lung cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07561567

• Combining nutrition checks and muscle measurements to predict outcomes after lung cancer surgery

  This project will test whether combining nutrition tests and muscle scans can predict recovery, complications, and short-term outcomes in adults having lung cancer surgery.

  Recruiting Ondokuz Mayıs University · Samsun, Samsun · NCT07500376

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Phase II test of SKB571 for advanced non-small cell lung cancer

  This study will test SKB571 given alone in adults with advanced non-small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou and 1 other locations · NCT07230405

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.